The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction

NACompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

December 1, 2018

Primary Completion Date

July 1, 2022

Study Completion Date

October 1, 2022

Conditions
Acute Myocardial Infarction
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet [Entresto]

Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.

Trial Locations (1)

21524

Andalusia Hospitals, Alexandria

All Listed Sponsors
lead

The Young Investigator Group of Cardiovascular Research

NETWORK

NCT03893435 - The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction | Biotech Hunter | Biotech Hunter